MA52214A - Composé hétérocyclique et son utilisation - Google Patents

Composé hétérocyclique et son utilisation

Info

Publication number
MA52214A
MA52214A MA052214A MA52214A MA52214A MA 52214 A MA52214 A MA 52214A MA 052214 A MA052214 A MA 052214A MA 52214 A MA52214 A MA 52214A MA 52214 A MA52214 A MA 52214A
Authority
MA
Morocco
Prior art keywords
heterocyclic compound
heterocyclic
compound
Prior art date
Application number
MA052214A
Other languages
English (en)
Inventor
Jumpei Aida
Masaki Daini
Mitsuhiro Ito
Kouichi Iwanaga
Hiroyuki Kakei
Makoto Kamata
Taku Kamei
Shigemitsu Matsumoto
Satoshi Mikami
Shinji Morimoto
Masataka Murakami
Minoru Nakamura
Shinji Nakamura
Yuya Oguro
Masaki Seto
Kazuaki Takami
Sachie Takashima
Taisuke Tawaraishi
Norihito Tokunaga
Yasufumi Wada
Takeshi Wakabayashi
Satoshi Yamamoto
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA52214A publication Critical patent/MA52214A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA052214A 2018-03-28 2019-03-27 Composé hétérocyclique et son utilisation MA52214A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018062939 2018-03-28

Publications (1)

Publication Number Publication Date
MA52214A true MA52214A (fr) 2021-04-21

Family

ID=66397395

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052214A MA52214A (fr) 2018-03-28 2019-03-27 Composé hétérocyclique et son utilisation

Country Status (17)

Country Link
US (2) US10807987B2 (fr)
EP (1) EP3774800B1 (fr)
JP (1) JP7279067B2 (fr)
KR (1) KR20200136957A (fr)
CN (1) CN111936495A (fr)
AR (1) AR115020A1 (fr)
AU (1) AU2019241765B2 (fr)
BR (1) BR112020018238A2 (fr)
CA (1) CA3100133A1 (fr)
EA (1) EA202092294A1 (fr)
ES (1) ES3006012T3 (fr)
IL (1) IL276912A (fr)
MA (1) MA52214A (fr)
MX (1) MX2020010148A (fr)
SG (1) SG11202008519RA (fr)
TW (1) TW202003519A (fr)
WO (1) WO2019189945A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (fr) * 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5252563A (en) * 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
JP3439551B2 (ja) * 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CA2214247C (fr) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
EP1586584A1 (fr) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulateurs de l'agrégation de peptides beta-amyloides, comprenant des D-aminoacides
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1194449B1 (fr) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibiteurs de memapsine 2 et son utilisation
EP1390034A4 (fr) * 2001-04-03 2005-07-13 Merck & Co Inc Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
JP2004161716A (ja) * 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
CA2521907A1 (fr) * 2003-04-10 2004-10-21 Pfizer Inc. Composes bicycliques comme antagonistes du recepteur nr2b
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
AU2010210426B2 (en) * 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP2694509B1 (fr) * 2011-04-05 2016-05-18 Pfizer Limited Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6827757B2 (ja) 2016-10-11 2021-02-10 鬼怒川ゴム工業株式会社 ウエザーストリップ取付用クリップ
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (fr) * 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
WO2020196828A1 (fr) 2019-03-28 2020-10-01 武田薬品工業株式会社 Composé hétérocyclique contenant de l'azote

Also Published As

Publication number Publication date
US20190300536A1 (en) 2019-10-03
AU2019241765A1 (en) 2020-11-12
CN111936495A (zh) 2020-11-13
SG11202008519RA (en) 2020-10-29
EP3774800C0 (fr) 2024-11-13
CA3100133A1 (fr) 2019-10-03
EA202092294A1 (ru) 2021-01-15
AU2019241765A8 (en) 2021-02-18
IL276912A (en) 2020-10-29
EP3774800A1 (fr) 2021-02-17
AU2019241765B2 (en) 2022-07-07
KR20200136957A (ko) 2020-12-08
ES3006012T3 (en) 2025-03-17
EP3774800B1 (fr) 2024-11-13
JP7279067B2 (ja) 2023-05-22
US20210332053A1 (en) 2021-10-28
AR115020A1 (es) 2020-11-18
TW202003519A (zh) 2020-01-16
WO2019189945A8 (fr) 2020-10-15
WO2019189945A1 (fr) 2019-10-03
JP2021519294A (ja) 2021-08-10
BR112020018238A2 (pt) 2020-12-29
US11702419B2 (en) 2023-07-18
MX2020010148A (es) 2020-12-07
US10807987B2 (en) 2020-10-20

Similar Documents

Publication Publication Date Title
EP3816153A4 (fr) Composé hétérocyclique et son utilisation
EP3816154A4 (fr) Composé hétérocyclique et son application
EP3663281A4 (fr) Composé hétérocyclique et son application
EP4071145A4 (fr) Composé inhibiteur de jak et son utilisation
EP3932919A4 (fr) Composé inhibiteur de jak et son utilisation
EP3896060A4 (fr) Composé hétérocyclique
EP3895707A4 (fr) Composé hétérocyclique
EP3798219A4 (fr) Composé de dihydronaphtyridine substitué par phényle et son utilisation
MA43963A (fr) Composé de pipéridine substituée et son utilisation
EP3929199A4 (fr) Nouveau composé hétérocyclique et utilisation associée
EP3689879A4 (fr) Composé hétérocyclique
EP3521301A4 (fr) Composé polyamide et son utilisation
MA54823A (fr) Composé hétérocyclique et son utilisation
EP3687989A4 (fr) Composé de pyrimidine pipérazine substitué et son utilisation
EP3792248A4 (fr) Composé benzamide et son application
EP3674352A4 (fr) Composé dérivé de lignine et son utilisation
EP3950674A4 (fr) Composé pyrrole amide et son utilisation
EP3890738A4 (fr) Composé macrocyclique et son utilisation
EP3888652A4 (fr) Composé hétérocyclique
EP3981769A4 (fr) Composé de pyrrolopyrimidine et son utilisation
EP3681877A4 (fr) Composé dérivé de pyrazole et son utilisation
EP3514153A4 (fr) Composé pyrimidine et son utilisation pharmaceutique
EP3660003A4 (fr) Composé hétérocyclique
EP3696163A4 (fr) Nouveau composé pseudocéramide et son utilisation
EP3578549A4 (fr) Composé hétérocyclique